.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,737,142

« Back to Dashboard
Patent 7,737,142 protects VRAYLAR and is included in one NDA.

This patent has thirty-two patent family members in thirty countries.

Summary for Patent: 7,737,142

Title:(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Abstract: The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): ##STR00001## wherein R.sub.1 and R.sub.2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R.sub.1 and R.sub.2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.
Inventor(s): Againe Csongor; Eva (Budapest, HU), Galambos; Janos (Budapest, HU), Nogradi; Katalin (Budapest, HU), Vago; Istvan (Budapest, HU), Gyertyan; Istvan (Budapest, HU), Kiss; Bela (Budapest, HU), Laszlovszky; Istvan (Budapest, HU), Laszy; Judit (Nagykovacsi, HU), Saghy; Katalin (Budapest, HU)
Assignee: Richter Gedeon Vegyeszeti Gyar Rt. (Budapest, HU)
Application Number:11/337,275
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 6th percentile
Forward Citations: 7th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Forest Res Inst Inc
VRAYLAR
cariprazine hydrochloride
CAPSULE;ORAL204370-001Sep 17, 2015RXNo7,737,142► subscribeYY TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
Forest Res Inst Inc
VRAYLAR
cariprazine hydrochloride
CAPSULE;ORAL204370-002Sep 17, 2015RXNo7,737,142► subscribeYY TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
Forest Res Inst Inc
VRAYLAR
cariprazine hydrochloride
CAPSULE;ORAL204370-003Sep 17, 2015RXNo7,737,142► subscribeYY TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,737,142

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
HungaryP0302451Aug 4, 2003

International Patent Family for Patent: 7,737,142

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia1663996► subscribe
Serbia52771► subscribe
Serbia20060041► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc